IGHE and ovarian carcinoma: MOv18-IgE has been confirmed to have both ADCC and ADCP capabilities mediated by FcεRI and CD23, respectively [26,28], and has been shown in vitro to drive ovarian cancer cell death by activating immune effector cells such as monocytes, macrophages, and mast cells [92].